{"version":"1.0","type":"rich","width":"560px","height":"140px","title":"Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)","url":"https:\/\/www.myelomasociety.org\/isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-final-progression-free-survival-analysis-of-part-1-of-a\/","author_name":"IMSound","author_url":"https:\/\/www.myelomasociety.org","thumbnail_url":"https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2024\/07\/IMSound-Logo-only-v2.png","html":"<iframe width=\"560px\" height=\"140px\" src=\"https:\/\/www.myelomasociety.org\/isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-final-progression-free-survival-analysis-of-part-1-of-a\/?standalonePlayer\"><\/iframe>"}